Top Tweets for #cdk2
Menyongsong era Tahura, CDK II berperan aktif dalam konservasi & perlindungan melalui diskusi bersama DLHK hari ini. Menjaga Gunung Muria yang tetap lestari! 🌳⛰️
#TahuraMuria #CDK2 #Konservasi #GunungMuria #Ngopeninglakoni
@DwiCahyoPurnom8
@dlhkprovjateng
Attending #SABCS25?
Don’t miss the poster sessions exploring #CDK2 inhibition as a novel strategy to help close critical gaps in #breastcancer treatment. Exciting science pointing toward new possibilities for patients and clinicians.
More details here🔬: https://t.co/w95nJZnoOH
Today's $NVS deal w/ $GLUE large outlier v peers, total value $5.7B, wonder what target is?!
Here are just a few deals for comparison by target:
#VAV1 - $NVS $GLUE
#STAT6 - $JNJ $KYMR $NRIX $GILD $SNY
#IRAK4 - $SNY $KYMR
#CDK2 - $GLD $KYMR https://t.co/KuzqSTdhGA
$JNJ $SNY $GILD shown strong interest in oral downstream #STAT6 inhibitors/degraders for #Th2 diseases. Avg partner deal = $120M upfront and up to $1.8B milestones + royalties.
Most programs remain in preclinical or Phase 1, no clinical readouts yet, first data due in 2025.
$NRIX and $KYMR small bios in mix
$KYMR pipeline resets/changes since Feb '25:
- Halt #TKY2 program
- Dropped most advanced #IRAK4 KT-474 (Ph2b for HS + AD) for back-up KT-485 (IND), $SNY
- Added #IRF5 (IND)
- Partnered #CDK2 w/ $GILD (Preclin)
Ph1b atopic dermatitis #STAT6 degr KT-621 most advanced, data 4Q25
Truist $KYMR current levels reflect ~$10-$12/sh to IRAK4 program with majority of value for STAT6 program. Pushing out IRAK4 program by ~3 years could impact stock by $3-$4/sh, by estimates. With delay in Kymera's IRAK4 program we see potential for increased competition
Now open @utswcancer: A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability,
Pharmacokinetics, and Efficacy of INX-315 in Patients with Advanced Cancer, NCT05735080.
#CDK2 #CCNE1 #fulvestrant #clinicaltrials #BreastCancer #ovariancancer @incyclixbio
The FDA has granted Incyclix Bio Fast Track designation for INX-315 to treat ovarian #cancer. The company’s lead compound is being evaluated in an ongoing, first-human Phase 1/2 clinical trial. Read more at: https://t.co/EM96U9Gydi
Falchook et al. summarize past and current CDK2 inhibitors in clinical trials in this #JIPO review https://t.co/wL8xIMzuk4 #CDK2 #clinicaltrial #JIPO @OncologyNetwork
Discrete vulnerability to pharmacological #CDK2 inhibition is governed by heterogeneity of the cancer cell cycle | Nature Communications https://t.co/7LjjFr5xuS
#biomedicines
Let’s take a look at this beautiful #GraphicAbstract: 🐱
Title: 🚜ADMET and Solubility Analysis of New 5-Nitroisatine-Based Inhibitors of #CDK2 Enzymes 🐧
Link: 🌵
https://t.co/105ou5f9Gq
@MDPIOpenAccess @MDPIBiologySubj
New review article from @Poulikos and colleagues, "Resistance Mechanisms and Therapeutic Strategies for CDK4/6 Kinase Targeting in Cancer," in @NatureCancer
https://t.co/0oMYiaeum0
@ProfGavathiotis @ChrAdamopoulos #PROTACs #CDK46 #CDK2 #Oncology #CancerImmunotherapy
Our review article, "Resistance Mechanisms and Therapeutic Strategies for CDK4/6 Kinase Targeting in Cancer," is out today in @NatureCancer ! Check it out.
https://t.co/XnpdyPDbxP
@ProfGavathiotis @ChrAdamopoulos
#PROTACs #CDK46 #CDK2 #Oncology #CancerImmunotherapy
At #ESMO24 #MatteoSimonelli @HUNIMED @HumanitasMilano presents phase 1 data of #INCB123667 a #CDK2 inhibitor in patients with advanced solid tumors @myESMO #ESMOAmbassadors
ICYMI in @CD_AACR: INX-315, a Selective #CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors - by Catherine Dietrich, Alec Trub, Patrick Roberts, @shomgoel, and colleagues #ESMO24 https://t.co/fdzItoI1hj @incyclixbio @PeterMacCC
From the latest issue—
INX-315, a Selective #CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors, by Catherine Dietrich, Alec Trub, Patrick Roberts, @shomgoel et al.
https://t.co/yJek0PEJcN
@incyclixbio @PeterMacCC
From the March issue—
INX-315, a Selective #CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors, by Catherine Dietrich, Alec Trub, Patrick Roberts, @shomgoel et al.
https://t.co/PoXIJEiXOg
@incyclixbio @PeterMacCC
New research published in @CD_AACRo describes INX-315’s antitumor activity and ability to overcome drug resistance in #cancer. Learn more about our potent and selective #CDK2 inhibitor from our collaboration with @shomgoel and @PeterMacRes: https://t.co/GS0LMiSlw4
Research by @shomgoel and his lab, published in Cancer Discovery reports on a potent & selective CDK2 inhibitor developed by Incyclix Bio. The study shows that inhibiting CDK2 pharmacologically is a very promising strategy for 2 groups of high-risk cancers
https://t.co/qdwziHlxdN
#OnlineFirst: INX-315, a Selective #CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors, by Catherine Dietrich, Alec Trub, Patrick Roberts, @shomgoel et al.
https://t.co/DiGe77fPmN
@incyclixbio @PeterMacCC
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
241M followers
Barack Obama
@barackobama
119.2M followers
Cristiano Ronaldo
@cristiano
112M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.2M followers
KATY PERRY
@katyperry
88.5M followers
Taylor Swift
@taylorswift13
82.3M followers
Lady Gaga
@ladygaga
73.9M followers
Virat Kohli
@imvkohli
71.2M followers
Kim Kardashian
@kimkardashian
70.2M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.3M followers
Neymar Jr
@neymarjr
64M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.5M followers
X
@x
60.8M followers